Literature DB >> 1661618

Interleukin-2 induces chemotactic deficiency in patients with onco hematologic malignancies and autologous bone marrow transplantation.

A M Stoppa1, C Fossat, D Blaise, P Viens, M Brandely, C N Pourreau, D Sainty, G Novakovitch, M Miquel, I Juhan-Vague.   

Abstract

Unusual gram positive bacteremia has been reported in non granulopenic patients receiving recombinant human interleukin-2 (IL-2) suggesting a beneficial effect of anti gram positive prophylaxis in such patients. We report here studies on granulocyte functions examined during the course of high dose IL-2 therapy (16 to 24 million IU/m2/days for 11 to 18 days) administered during a period of 35 days in 14 patients including 4 solid tumors, 5 chronic myeloid leukemias, 4 recipients of autologous bone marrow transplant (ABMT) and 1 recipient of syngeneic bone marrow transplant. Neutrophils functions were studied before IL-2 administration (d 0), after the first cycle (d 8) and after the third cycle (d 36). Nylon fiber adherence, superoxide production, random migration, phagocytosis, nitroblue tetrazolium reduction, lysozyme and elastase release were not impaired significantly throughout therapy. However N-Formyl-Methionyl-Leucyl-Phenylalanine (FMLP) stimulated chemotaxis of granulocytes, normal before therapy, was significantly impaired as early at d 8 and severely inhibited at d 36 (p less than 0.001). Three septicemia, one corynebacteria parvum septicemia and two gram-negative septicemia despite normal neutrophil counts and oxacillin or Penicillin G plus Pefloxacin prophylaxis, occurred among the 14 patients studied. Although neutrophil functions were not more depressed in transplanted patients than in the other non transplanted patients, special attention should be paid to such patients in whom delayed immune reconstitution could increase the risk of sepsis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661618

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  3 in total

1.  Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

Authors:  Marc Buyse; Pierre Squifflet; Beverly J Lange; Todd A Alonzo; Richard A Larson; Jonathan E Kolitz; Stephen L George; Clara D Bloomfield; Sylvie Castaigne; Sylvie Chevret; Didier Blaise; Dominique Maraninchi; Kathryn J Lucchesi; Tomasz Burzykowski
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

2.  Hyperactive polymorphonuclear leucocytes migration in patients with Familial Mediterranean Fever.

Authors:  P Disdier; C Fossat; V Veit; M David; L Swiader; J R Harle; I Juhan-Vague; P J Weiller
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

Review 3.  Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission.

Authors:  Chen Mao; Xiao-Hong Fu; Jin-Qiu Yuan; Zu-Yao Yang; Ya-Fang Huang; Qian-Ling Ye; Xin-Yin Wu; Xue-Feng Hu; Zhi-Min Zhai; Jin-Ling Tang
Journal:  Cochrane Database Syst Rev       Date:  2015-11-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.